TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Chongqing Peg-Bio Biopharm Co., Ltd.
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Apollo Therapeutics Ltd
Washington University School of Medicine
First Affiliated Hospital of Zhejiang University
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stanford University
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
AstraZeneca
Ohio State University Comprehensive Cancer Center
Oslo University Hospital
Prelude Therapeutics
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Magenta Therapeutics, Inc.
New York Medical College
Bellicum Pharmaceuticals
Baylor College of Medicine
Jasper Therapeutics, Inc.
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University College, London
Dana-Farber Cancer Institute
University of Washington
The Netherlands Cancer Institute
Pfizer
M.D. Anderson Cancer Center
Eli Lilly and Company
Stanford University
AbbVie
Masonic Cancer Center, University of Minnesota
AbbVie
GlaxoSmithKline
Thomas Jefferson University
Fred Hutchinson Cancer Center
Yale University
Altor BioScience
University Health Network, Toronto
University Health Network, Toronto
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center